LAG‐3 inhibitors interact with LAG‐3 ligands on the surface of T‐cells to block T‐regulatory (Treg) cell activity, suppress cytokine secretion and restore dysfunctional effector T‐cells which subsequently attack and destroy cancer cells. Here, LAG3 is linked to cancer.